The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis
Open accessAbstract
Introduction: Regenerative medicine and particular adult stem cells represent an alternative option with several fruitful therapeutic applications in patients suffering from chronic lung diseases including idiopathic pulmonary fibrosis (IPF). Nevertheless, lack of knowledge regarding the origin and the potential of mesenchymal stem cells (MSCs) to differentiate into fibroblasts has limited their use for the treatment of this dismal disease. Patients and methods: To this end, we conducted a phase Ib, non-randomized, clinical trial to study the safety of three endobronchial infusions of autologous adipose derived stromal cells (ADSCs)-stromal vascular fraction (SVF) (0.5 million cells per kgr of body weight per infusion) in patients with IPF (n=14) of mild to moderate disease severity (forced vital capacity –FVC>50% predicted value and diffusion lung capacity for carbon monoxide-DL CO >35% of predicted value). Our primary end-point was incidence of treatment emergent adverse events within 12 months. Alterations of functional, exercise capacity and quality of life parameters at serial time points (baseline, 6 and 12 months after first infusion) were exploratory secondary end-points. Results: No cases of serious or clinically meaningful adverse events including short-term infusional toxicities as well as long-term ectopic tissue formation were recorded in all patients. Detailed safety monitoring through several time-points indicated that cell-treated patients did not deteriorate in both functional parameters and indicators of quality of life. Conclusions: The clinical trial met its primary objective demonstrating an acceptable safety profile of endobronchially administered autologous ADSCs-SVF. Our findings accelerate the rapidly expanded scientific knowledge and indicate a way towards future efficacy trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Preclinical research showed prostaglandins are protective against fibrosis in bleomycin induced lung injury, and platelet produced thromboxane A2 (TXA2) leads to platelet aggregation and smooth muscle contraction [167].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [167]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The balance between the anti-fibrotic prostaglandin and profibrotic TXA2 as evidenced by a decreased prostacyclin to TXA2 ratio has also been associated with pulmonary fibrosis [167,168].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [167]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Evidence for Human Lung Stem Cells
Kajstura, J., Rota, M., Hall, S. R., Hosoda, T., D'Amario, D., Sanada, F., Zheng, H., Ogórek, B., Rondon-Clavo, C., Ferreira-Martins, J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1101324 · Cited by 380
RetractedDominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationHuman Adipose Tissue Is a Source of Multipotent Stem Cells
Zuk, P. A., Zhu, M., Ashjian, P., De Ugarte, D. A., Huang, J. I., Mizuno, H., Alfonso, Z. C., Fraser, J. K., Benhaim, P., & Hedrick, M. H. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-02-0105 · Cited by 6,664
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Bourin, P., Bunnell, B. A., Casteilla, L., Dominici, M., Katz, A. J., March, K. L., Redl, H., Rubin, J. P., Yoshimura, K., & Gimble, J. M. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.02.006 · Cited by 1,890 · cited 3×
“Based on the recently published statement of International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT) [20], SVF is a supportive stroma lying within adipose tissue, which represents an abundant and easily accessible source of a heterogeneous cell po…”
MethodMeisel, R., Zibert, A., Laryea, M., Göbel, U., Däubener, W., & Dilloo, D. (2004) · Blood · doi:10.1182/blood-2003-11-3909 · Cited by 1,646
Ortiz, L. A., Gambelli, F., McBride, C., Gaupp, D., Baddoo, M., Kaminski, N., & Phinney, D. G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432929100 · Cited by 1,445
Hare, J. M., Traverse, J. H., Henry, T. D., Dib, N., Strumpf, R. K., Schulman, S. P., Gerstenblith, G., DeMaria, A. N., Denktas, A. E., Gammon, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.06.055 · Cited by 1,350
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310 · cited 1×
“With a gradually increasing worldwide [6] incidence and in view of the current disappointing status of available pharmaceutical agents the need for developing new treatments for IPF that are safe, effective and tolerable is now more challenging than ever [7].”
Background
Cited by
Fibrosis–a common pathway to organ injury and failure
Rockey, D. C., Bell, P. D., & Hill, J. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300575 · Cited by 1,428
Martinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., Swigris, J. J., Taniguchi, H., & Wells, A. U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.74 · Cited by 1,388
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development
Spagnolo, P., Kropski, J. A., Jones, M. G., Lee, J. S., Rossi, G., Karampitsakos, T., Maher, T. M., Tzouvelekis, A., & Ryerson, C. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107798 · Cited by 636
Self-citationInhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis
Dinh, P.-U. C., Paudel, D., Brochu, H., Popowski, K. D., Gracieux, M. C., Cores, J., Huang, K., Hensley, M. T., Harrell, E., Vandergriff, A. C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14344-7 · Cited by 435
Chambers, D. C., Enever, D., Ilic, N., Sparks, L., Whitelaw, K., Ayres, J., Yerkovich, S. T., Khalil, D., Atkinson, K. M., & Hopkins, P. M. A. (2014) · Respirology · doi:10.1111/resp.12343 · Cited by 278
Metadata
- Authors
- Tzouvelekis, A., Paspaliaris, V., Koliakos, G., Ntolios, P., Bouros, E., Oikonomou, A., Zissimopoulos, A., Boussios, N., Dardzinski, B., Gritzalis, D., Antoniadis, A., Froudarakis, M., Kolios, G., & Bouros, D.
- Affiliations
- National Hellenic Research Foundation (GR)
- Democritus University of Thrace (GR)
- IASO General Hospital (GR)
- General Hospital of Serres (GR)
- Corresponding author
- Bouros, Demosthenes
- ORCID
- Venue
- Journal of Translational Medicine
- Published
- 2013-07-15
- Volume
- 11
- Issue
- 1
- Pages
- 171-171
- ISSN
- 1479-5876 (ISSN-L)
- PMC
- PMC3722100
- OpenAlex
- W2122083530
- Cited by
- 255
- References
- 68
- Citations by year
- 2026: 10 · 2025: 8 · 2024: 11 · 2023: 14 · 2022: 19 · 2021: 35 · 2020: 19 · 2019: 22 · 2018: 17 · 2017: 30 · 2016: 19 · 2015: 24 · 2014: 20 · 2013: 5
- FWCI
- 11.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Translational Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Research Foundation
- Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, adipose-derived stromal cells, stromal vascular fraction, autologous cell therapy, treatment safety, adverse events, mesenchymal stem cells, regenerative medicine, quality of life, exercise capacity
- MeSH terms
- Adipose Tissue, Aged, Female, Flow Cytometry, Humans, Inflammation, Lung, Male, Middle Aged, Prospective Studies, Radionuclide Imaging, Respiratory Function Tests, Stromal Cells, Idiopathic Pulmonary Fibrosis, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1186/1479-5876-11-171
- The paper
- Tzouvelekis, A., Paspaliaris, V., Koliakos, G., Ntolios, P., Bouros, E., Oikonomou, A., Zissimopoulos, A., Boussios, N., Dardzinski, B., Gritzalis, D., Antoniadis, A., Froudarakis, M., Kolios, G., & Bouros, D. (2013). A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-11-171
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.